U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H40BrN5O5
Molecular Weight 654.5952
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BROMOCRIPTINE

SMILES

CC(C)C[C@@]1([H])C(=O)N2CCC[C@@]2([H])[C@]3(N1C(=O)[C@](C(C)C)(N=C([C@]4([H])C=C5c6cccc7c6c(C[C@@]5([H])N(C)C4)c(Br)[nH]7)O)O3)O

InChI

InChIKey=OZVBMTJYIDMWIL-AYFBDAFISA-N
InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020866lbl.pdf | https://www.drugs.com/mtm/bromocriptine.html

Bromocriptine is an ergot derivative with potent dopamine receptor agonist activity, which activates post-synaptic dopamine receptors. Bromocriptine is indicated for the treatment of dysfunctions associated with hyperprolactinemia. Bromocriptine therapy is indicated in the treatment of acromegaly and in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson’s disease. It is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Some commonly reported adverse reactions include nausea, fatigue, dizziness, vomiting and headache. Bromocriptine may interact with dopamine antagonists, butyrophenones and certain other agents.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
36.0 nM [Ki]
197.0 nM [Ki]
2.2 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
PARLODEL

Approved Use

Hyperprolactinemia-Associated Dysfunctions Bromocriptine mesylate tablets are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Bromocriptine mesylate tablets treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine mesylate tablets therapy may be used to reduce the tumor mass prior to surgery. Acromegaly Bromocriptine mesylate tablets therapy is indicated in the treatment of acromegaly. Bromocriptine mesylate tablets therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. Since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine mesylate tablets offers potential benefit before the effects of irradiation are manifested. Parkinson's Disease Bromocriptine mesylate tablets are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson's disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate tablets therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing end of dose failure on levodopa therapy. Bromocriptine mesylate tablets therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function (on-off phenomenon). Continued efficacy of bromocriptine mesylate tablets therapy during treatment of more than 2 years has not been established. Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson's disease with bromocriptine mesylate tablets. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in bromocriptine mesylate treated patients than in levodopa/carbidopa treated patients. Patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets therapy.

Launch Date

2.67839996E11
Primary
PARLODEL

Approved Use

Hyperprolactinemia-Associated Dysfunctions Bromocriptine mesylate tablets are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Bromocriptine mesylate tablets treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine mesylate tablets therapy may be used to reduce the tumor mass prior to surgery. Acromegaly Bromocriptine mesylate tablets therapy is indicated in the treatment of acromegaly. Bromocriptine mesylate tablets therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. Since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine mesylate tablets offers potential benefit before the effects of irradiation are manifested. Parkinson's Disease Bromocriptine mesylate tablets are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson's disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate tablets therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing end of dose failure on levodopa therapy. Bromocriptine mesylate tablets therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function (on-off phenomenon). Continued efficacy of bromocriptine mesylate tablets therapy during treatment of more than 2 years has not been established. Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson's disease with bromocriptine mesylate tablets. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in bromocriptine mesylate treated patients than in levodopa/carbidopa treated patients. Patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets therapy.

Launch Date

2.67839996E11
Primary
PARLODEL

Approved Use

Hyperprolactinemia-Associated Dysfunctions Bromocriptine mesylate tablets are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Bromocriptine mesylate tablets treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine mesylate tablets therapy may be used to reduce the tumor mass prior to surgery. Acromegaly Bromocriptine mesylate tablets therapy is indicated in the treatment of acromegaly. Bromocriptine mesylate tablets therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. Since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine mesylate tablets offers potential benefit before the effects of irradiation are manifested. Parkinson's Disease Bromocriptine mesylate tablets are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson's disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate tablets therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing end of dose failure on levodopa therapy. Bromocriptine mesylate tablets therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function (on-off phenomenon). Continued efficacy of bromocriptine mesylate tablets therapy during treatment of more than 2 years has not been established. Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson's disease with bromocriptine mesylate tablets. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in bromocriptine mesylate treated patients than in levodopa/carbidopa treated patients. Patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets therapy.

Launch Date

2.67839996E11
Primary
CYCLOSET

Approved Use

Drug is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Launch Date

1.24139523E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
628 pg/mL
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BROMOCRIPTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2377 pg × h/mL
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BROMOCRIPTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.85 h
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BROMOCRIPTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BROMOCRIPTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
4.8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 4.8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 4.8 mg, 1 times / day
Sources: Page: p.3
unhealthy, 27-80
n = 3070
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Age Group: 27-80
Sex: M+F
Population Size: 3070
Sources: Page: p.3
Disc. AE: Nausea...
AEs leading to
discontinuation/dose reduction:
Nausea
Sources: Page: p.3
4.8 mg 1 times / day multiple, oral
MTD
Dose: 4.8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 4.8 mg, 1 times / day
Sources: Page: p.1691, 1699
unhealthy, 55+/-1
n = 314
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Age Group: 55+/-1
Sex: M+F
Population Size: 314
Sources: Page: p.1691, 1699
Disc. AE: Nausea, Dizziness...
AEs leading to
discontinuation/dose reduction:
Nausea (4%)
Dizziness (2.8%)
Asthenia (1.5%)
Rhinitis (1.5%)
Sources: Page: p.1691, 1699
4.8 mg 1 times / day multiple, oral
MTD
Dose: 4.8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 4.8 mg, 1 times / day
Sources: Page: p.1505, 1507
unhealthy, 59.5 +/- 10.2
n = 2054
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Age Group: 59.5 +/- 10.2
Sex: M+F
Population Size: 2054
Sources: Page: p.1505, 1507
Disc. AE: Nausea...
AEs leading to
discontinuation/dose reduction:
Nausea
Sources: Page: p.1505, 1507
100 mg 1 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy
300 mg single, oral
Highest studied dose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources: Page: p.978
unhealthy
n = 1
Health Status: unhealthy
Condition: Parkinson's Disease
Population Size: 1
Sources: Page: p.978
30 mg 1 times / day multiple, oral (total)
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Prolactinomas|Hypogonadism|Galactorrhea syndromes|Infertility
Sources:
AEs

AEs

AESignificanceDosePopulation
Nausea Disc. AE
4.8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 4.8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 4.8 mg, 1 times / day
Sources: Page: p.3
unhealthy, 27-80
n = 3070
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Age Group: 27-80
Sex: M+F
Population Size: 3070
Sources: Page: p.3
Asthenia 1.5%
Disc. AE
4.8 mg 1 times / day multiple, oral
MTD
Dose: 4.8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 4.8 mg, 1 times / day
Sources: Page: p.1691, 1699
unhealthy, 55+/-1
n = 314
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Age Group: 55+/-1
Sex: M+F
Population Size: 314
Sources: Page: p.1691, 1699
Rhinitis 1.5%
Disc. AE
4.8 mg 1 times / day multiple, oral
MTD
Dose: 4.8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 4.8 mg, 1 times / day
Sources: Page: p.1691, 1699
unhealthy, 55+/-1
n = 314
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Age Group: 55+/-1
Sex: M+F
Population Size: 314
Sources: Page: p.1691, 1699
Dizziness 2.8%
Disc. AE
4.8 mg 1 times / day multiple, oral
MTD
Dose: 4.8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 4.8 mg, 1 times / day
Sources: Page: p.1691, 1699
unhealthy, 55+/-1
n = 314
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Age Group: 55+/-1
Sex: M+F
Population Size: 314
Sources: Page: p.1691, 1699
Nausea 4%
Disc. AE
4.8 mg 1 times / day multiple, oral
MTD
Dose: 4.8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 4.8 mg, 1 times / day
Sources: Page: p.1691, 1699
unhealthy, 55+/-1
n = 314
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Age Group: 55+/-1
Sex: M+F
Population Size: 314
Sources: Page: p.1691, 1699
Nausea Disc. AE
4.8 mg 1 times / day multiple, oral
MTD
Dose: 4.8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 4.8 mg, 1 times / day
Sources: Page: p.1505, 1507
unhealthy, 59.5 +/- 10.2
n = 2054
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Age Group: 59.5 +/- 10.2
Sex: M+F
Population Size: 2054
Sources: Page: p.1505, 1507
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Drug as perpetrator​Drug as victim
PubMed

PubMed

TitleDatePubMed
Clinical features and medical treatment of male prolactinomas.
2001
Dopamine agonists.
2001
Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
2001
Treatment of systemic lupus erythematosus with bromocriptine.
2001
Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study.
2001
Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
2001
Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
2001
Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin's lymphomas at advanced stage: results of a phase II trial.
2001 Apr
[Increased T1 signal of the residual normal anterior pituitary gland following medical treatment of pituitary prolactinoma].
2001 Apr
The role of hypertension in bromocriptine-related puerperal intracranial hemorrhage.
2001 Apr
Alpha-dihydroergocryptine and predictive factors in migraine prophylaxis.
2001 Apr
Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation.
2001 Apr
In vivo and in vitro effects of prolactin and growth hormone on lipid metabolism in a teleost, Anabas testudineus (Bloch).
2001 Apr
Cortical effects of bromocriptine, a D-2 dopamine receptor agonist, in human subjects, revealed by fMRI.
2001 Apr
Polysomnographic measures in Parkinson's disease: a comparison between patients with and without REM sleep disturbances.
2001 Apr 17
Bromocriptine in rheumatic and autoimmune diseases.
2001 Aug
Luteolytic effect of prolactin is dependent on the degree of differentiation of luteal cells in the rat.
2001 Aug
Neuroleptic malignant syndrome without neuroleptics.
2001 Feb
Dose-dependent augmentation effect of bromocriptine in a case with refractory depression.
2001 Feb
Bromocriptine-induced dissociation of hyperglycemia and prolactin response to restraint.
2001 Feb
Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases.
2001 Feb
[Decreased tumor size in hypophyseal macroadenoma--empty sella syndrome].
2001 Feb 15
Effects of bromocriptine in a patient with crossed nonfluent aphasia: a case report.
2001 Jan
[Pharmacological effects of cabergoline against parkinsonism].
2001 Jun
Pituitary prolactin-secreting macroadenoma combined with bilateral breast cancer in a 45-year-old male.
2001 Jun
Neuroleptic malignant syndrome during a change from haloperidol to risperidone.
2001 Jun
The effect of prolactin and bromocriptine on human peripheral immune status.
2001 Mar
Polycystic ovary syndrome and hyperprolactinemia.
2001 Mar
Contribution of growth hormone-releasing hormone and somatostatin to decreased growth hormone secretion in elderly men.
2001 Mar
Positive outcomes in traumatic brain injury-vegetative state: patients treated with bromocriptine.
2001 Mar
Bromocriptine administration lowers serum prolactin and disrupts parental responsiveness in common marmosets (Callithrix j. jacchus).
2001 Mar
Evaluation of the male pubertal assay's ability to detect thyroid inhibitors and dopaminergic agents.
2001 Mar
Effects of chronic bromocriptine treatment on tyrosine hydroxylase (TH) mRNA expression, TH activity and median eminence dopamine concentrations in ageing rats.
2001 Mar
Dopamine modulates sodium currents in cochlear spiral ganglion neurons.
2001 Mar 26
[Parkinson disease: diagnostic and therapeutic criteria].
2001 Mar 3
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.
2001 Mar 9
[A-56-year-old woman with parkinsonism, whose mother had Parkinson's disease].
2001 May
Central bromocriptine-induced tachycardia is reversed to bradycardia in conscious, deoxycorticosterone acetate-salt hypertensive rats.
2001 May
Pituitary tumours in adolescence: clinical behaviour and neuroimaging features of seven cases.
2001 May
Increased responsiveness to the hyperglycemic, hyperglucagonemic and hyperinsulinemic effects of circulating norepinephrine in ob/ob mice.
2001 May
Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice.
2001 May
Fertile estrus induced in bitches by bromocryptine, a dopamine agonist: a clinical trial.
2001 May 1
Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism.
2001 May 18
Study of the change of prolactin and progesterone during dopaminergic agonist treatments in pseudopregnant bitches.
2001 May 31
[Cerebral meningeal hemorrhage and acute cerebral angiopathy associated with the taking of phenylpropanolamine: a new case].
2001 May-Jun
Biphasic effects of 7-OH-DPAT on the acquisition of responding for conditioned reward in rats.
2001 May-Jun
Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study.
2001 May-Jun
Double-blind, crossover, placebo-controlled trial of bromocriptine in patients with sleep bruxism.
2001 May-Jun
Differential signalling of both wild-type and Thr(343)Arg dopamine D(2short) receptor by partial agonists in a G-protein-dependent manner.
2001 Sep 15
Clinical management of neuroleptic malignant syndrome.
2001 Winter
Patents

Sample Use Guides

Type 2 diabetes mellitus: Initial dose is one tablet (0.8 mg) daily increased weekly by one tablet until maximal tolerated daily dose of 1.6 to 4.8 mg is achieved. Hyperprolactinemic Indications: The initial dosage in adults is ½ to one 2½ mg scored tablet daily. An additional 2½ mg tablet may be added to the treatment regimen as tolerated every 2-7 days until an optimal therapeutic response is achieved. The therapeutic dosage ranged from 2.5-15 mg daily in adults studied clinically. Parkinson’s Disease: The initial dose is ½ of a 2½ mg twice daily with meals. Assessments are advised at 2-week intervals during dosage titration to ensure that the lowest dosage producing an optimal therapeutic response is not exceeded. If necessary, the dosage may be increased every 14-28 days by 2½ mg/day with meals.
Route of Administration: Oral
Bromocriptine has been shown to augment glutamate uptake at a concentration of 10 uM in HeLaS3 cells that stably express EAAT1, the human homolog of GLAST. Therefore, it was evaluated whether bromocriptine affects D-[3 H]aspartate uptake in HEK293/EcR cells expressing EAAT2. However, bromocriptine failed to alter D-[3 H]aspartate uptake at concentrations as high as 30 uM, suggesting that bromocriptine has little or no effect on the excitatory amino acid uptake via EAAT2.
Name Type Language
BROMOCRIPTINE
INN   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
SANDOZ 15-754
Code English
2-BROMO-.ALPHA.-ERGOCRYPTINE
Common Name English
BROMOCRIPTINE [USAN]
Common Name English
ERGOTAMAN-3',6',18-TRIONE, 2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(2-METHYLPROPYL)-, (5'.ALPHA.)-
Common Name English
ERGOCRYPTINE, 2-BROMO-
Common Name English
BROMOCRIPTINE [MI]
Common Name English
BROMOCRIPTINE [VANDF]
Common Name English
BROMOCRIPTINE [INN]
Common Name English
BROMOCRIPTINE [WHO-DD]
Common Name English
(+)-BROMOCRIPTINE
Systematic Name English
BROMERGOCRYPTINE
Common Name English
Classification Tree Code System Code
LIVERTOX 123
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
NDF-RT N0000175827
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
WHO-ATC N04BC01
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
NDF-RT N0000007618
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
NDF-RT N0000007618
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
NCI_THESAURUS C1509
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
WHO-ATC G02CB01
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
WHO-VATC QG02CB01
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
NCI_THESAURUS C66884
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
Code System Code Type Description
MESH
D001971
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
PRIMARY
EPA CompTox
25614-03-3
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
PRIMARY
IUPHAR
35
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
PRIMARY
FDA UNII
3A64E3G5ZO
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
PRIMARY
PUBCHEM
31101
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
PRIMARY
ECHA (EC/EINECS)
247-128-5
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
PRIMARY
NCI_THESAURUS
C62010
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
PRIMARY
EVMPD
SUB05918MIG
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
PRIMARY
RXCUI
1760
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
BROMOCRIPTINE
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
PRIMARY
INN
3365
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
PRIMARY
CAS
25614-03-3
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
PRIMARY
ChEMBL
CHEMBL493
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
PRIMARY
DRUG BANK
DB01200
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
PRIMARY
MERCK INDEX
M2694
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
PRIMARY Merck Index
LACTMED
Bromocriptine
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
PRIMARY
DRUG CENTRAL
403
Created by admin on Sat Jun 26 06:09:41 UTC 2021 , Edited by admin on Sat Jun 26 06:09:41 UTC 2021
PRIMARY